Ribozymes as therapeutic agents: are we getting closer?

MicroRNA-mediated regulation of melanoma.

The British journal of dermatology·2014

Suppression of the human carcinoma phenotype by an antioncogene ribozyme.

Methods in molecular medicine·2014

Molecular markers in melanoma.

The British journal of dermatology·2013

Anti-c-erb1B2 Ribozyme for Gene Therapy of Breast Cancer.

Methods in molecular medicine·2011

Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells.

Cancer gene therapy·2005

Hammerhead ribozymes as therapeutic agents for bladder cancer.

Molecular urology·2002

Somatic alterations in TP53, PIK3CA, and CCND1 reveal exposure-driven patterns in oral and oropharyngeal tumors.

Journal of the National Cancer Institute·2026

Inhibitors of IAP/XIAP enhance activity of sacituzumab govitecan.

Journal of the National Cancer Institute·2026

Examining the role of extrachromosomal DNA in lung cancer.

Journal of the National Cancer Institute·2026

Differential impact of lymphocytes on radiation response in autochthonous vs transplant murine sarcomas.

Journal of the National Cancer Institute·2026

Nitrate and nitrite intake and risk of colorectal cancer: a population-based cohort study.

Journal of the National Cancer Institute·2026

The joint association of clonal hematopoiesis of indeterminate potential and biological aging with cancer risk among 332,911 individuals.

Journal of the National Cancer Institute·2026

Transforming the treatment of autoimmune skin diseases: a journey through biologic therapies.

Expert opinion on biological therapy·2026

Specificity of the Interactions of Folate-Based Vectors with Folate Receptor-α.

The journal of physical chemistry. B·2026

Clinical predictors of early treatment response across systemic therapies in psoriasis: a prospective cohort study.

The Journal of dermatological treatment·2026

Nanobodies targeting SARS-CoV-2 variants.

Acta pharmaceutica Sinica. B·2026

In vivo CRISPR editing for cancer immunotherapy.

Frontiers in immunology·2026

Subcutaneous administration of antibody-drug conjugates: current challenges, emerging opportunities, and future perspectives.

Antibody therapeutics·2026

Related Experiment Videos

Ribozymes as therapeutic agents: are we getting closer?

Related Concept Videos

MicroRNA-mediated regulation of melanoma.

Suppression of the human carcinoma phenotype by an antioncogene ribozyme.

Molecular markers in melanoma.

Anti-c-erb1B2 Ribozyme for Gene Therapy of Breast Cancer.

Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells.

Hammerhead ribozymes as therapeutic agents for bladder cancer.

Somatic alterations in TP53, PIK3CA, and CCND1 reveal exposure-driven patterns in oral and oropharyngeal tumors.

Inhibitors of IAP/XIAP enhance activity of sacituzumab govitecan.

Examining the role of extrachromosomal DNA in lung cancer.

Differential impact of lymphocytes on radiation response in autochthonous vs transplant murine sarcomas.

Nitrate and nitrite intake and risk of colorectal cancer: a population-based cohort study.

The joint association of clonal hematopoiesis of indeterminate potential and biological aging with cancer risk among 332,911 individuals.

Transforming the treatment of autoimmune skin diseases: a journey through biologic therapies.

Specificity of the Interactions of Folate-Based Vectors with Folate Receptor-α.

Clinical predictors of early treatment response across systemic therapies in psoriasis: a prospective cohort study.

Nanobodies targeting SARS-CoV-2 variants.

In vivo CRISPR editing for cancer immunotherapy.

Subcutaneous administration of antibody-drug conjugates: current challenges, emerging opportunities, and future perspectives.

Related Experiment Videos

Ribozymes as therapeutic agents: are we getting closer?

Related Concept Videos

Related Articles